Multiple Myeloma

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting reference, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies, and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.